Galecto begins third phase II trial

The first patient has now received a dose of Galecto's drug candidate GB1211 in a crucial phase 1b/2a trial meant to assess its efficacy in treating liver cirrhosis.

Hans Schambye, president and CEO at Galecto. | Photo: Henriette Dan Bonde / PR

With the first dose administered, Galecto has now begun a third phase II trial – specifically a 1b/2a trial. The substance is being tested as a treatment for liver cirrhosis.

This makes it the third of the company's drug candidates to enter a mid-phase trial.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs